Medical/Pharmaceuticals
Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers
* QR052107B Tablet was safe and well tolerated in healthy volunteers across all tested doses, with no taste related adverse event at the anticipated therapeutic doses * Createrna initiated a clinical Phase 2 trial to study QR052107B Tablet at once-a-day (QD) dose in the treatment of refract...
2022-12-08 14:29
2848
BSR KOREA Introduces "Wizbiosolutions Inc." as "2022 Global Procurement Marketer"
SEOUL, South Korea, Dec. 7, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the inter...
2022-12-08 00:00
3257
Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022
WASHINGTON, Dec. 6, 2022 /PRNewswire/ -- TIANGEN, a high-tech biological enterprise, demonstrated its revolutionary nucleic acid extraction solution at Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), fromDec 4 to...
2022-12-06 21:04
2614
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)
* Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization inthe United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world includingChina. * ...
2022-12-06 21:01
3744
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030
* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36th new drug from the Ministry of Food and Drug Safety * Plans to enter the type 2 diabetes global market worth $71.4 billion * Provides new and broad treatment options for patients with insufficie...
2022-12-06 20:00
2411
SK Biopharmaceuticals Wins Export Award for Cenobamate
SK Biopharmaceuticals receives the '$100 million Export Tower' award, becoming the first Korean pharmacompany to earn this prestige with a single innovative anti-seizure medication, cenobamate Cenobamate achieves over $100 million in exports in two years after launching in the U.S. andEurope – t...
2022-12-06 08:00
2638
Meihua International Medical Technologies Co., Ltd. Appoints New CEO, CFO and Directors
YANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the appointments...
2022-12-05 22:33
3003
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project
HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the Acquisition of Dry Eye Disease...
2022-12-05 21:00
3551
Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform
SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that after three years of preparation, the Company's MDMOOC platf...
2022-12-05 20:30
2557
Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp
NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...
2022-12-05 20:00
2212
The First IBCC Unveiled in Hainan
SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- The first Integrated Bladder Cancer Center (IBCC) inHainan Province was inaugurated in Hainan General Hospital at the Hainan Provincial Urology Annual Meeting. A patient-centered facility, the IBCC serves to improve inpatient experiences as well as medical s...
2022-12-05 15:55
2120
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device at AES 2022
Poster session features a preliminary study result of potential seizure monitoring and detection for patients using SK Biopharmaceuticals' wearable device SK Biopharmaceuticals, Seoul National University Bundang Hospital plan to use Zero WiredTM to further pursue clinical research and develop it...
2022-12-05 08:00
2715
Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022
JINAN, China, Dec. 4, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies inChina that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study...
2022-12-04 17:00
2174
JelloX Biotech Leads Research in 3D Cancer Pathology as NCI Explores Potential
SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- JelloX Biotech is celebrating a robust year of research and product development milestones while showcasing the potential for 3D imaging and AI to be the future of cancer pathology. Presently, most cancer diagnosis is done through thinly sliced physic...
2022-12-03 09:58
3279
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
HAIKOU, China, Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onDecember 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NY...
2022-12-03 05:10
4561
Lakeshore Acquisition Corp I Shareholders Approve Business Combination with ProSomnus
SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (Nasdaq: LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus"...
2022-12-03 05:05
4832
Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022
JINAN, China, Dec. 2, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies inChina that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study...
2022-12-02 16:20
2030
Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
BEIJING, SHANGHAI and BOSTON, Dec. 1, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination withSHP2 inhibitor JAB-3312 in preclinical cancer models in a poster session during the 2022 European Society of Medica...
2022-12-02 08:30
2463
Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met
SUZHOU, China, Dec. 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced results of phase II clinical trial of pyrilutamide (KX-826), a poten...
2022-12-01 19:30
2844
111, Inc. Announces Third Quarter 2022 Unaudited Financial Results
SHANGHAI, Dec. 1, 2022 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the third quarter...
2022-12-01 15:33
3618
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24